StemCell Therapy

September is National Self Care Awareness Month, traditionally a time when "back to school"has always meant personal renewal, stretching yourself, and trying new things. Here's how to take care of yourself by eating a whole-food plant-based diet, according to Dr. Sari Eitches, an LA-based integrative internist whopromotes wellness through lifestyle choices and takes a holistic approach to personal health.

In an exclusive interview with The Beet, Dr. Eitches, a long-time vegan, talks about guiding her patients to a plant-based lifestyle, as well as what to look out for when transitioning to a vegan or plant-based approach to eating, and her love ofvegan cuisine from around the world. She leads by example and shows that a plant-based diet can optimize our bodys self-healing properties, by lowering inflammation and adding antioxidants to every meal.Lether advice will inspire you to nourish your body and start adding plants to your meals, and take care of you.

Dr. Eitches: I was just finishing my first year as a medical student and I was the least healthy I'd ever been. I was super addicted to caffeine and getting by with convenience food. One week, I signed up for a yoga retreat to reset and relax. The retreat center had a vegetarian dining hall and my teacher was a long-time raw vegan. I intended to eat a raw diet to cleanse at the week-long retreat, but I felt so incredible that I continued to follow the raw diet for two years and remain vegan 14+ years later.

Dr. Eitches: I was pretty fascinated by the vast data that the majority of chronic conditions that Americans suffer from can be controlled, prevented, or even reversed with lifestyle changes including a plant-based diet. We literally are what we eat. The food choices we make (or are made for us) can either cause inflammation and accelerate chronic disease or, if we choose whole food plant-based diet, for example, our foods can slow, reverse and prevent chronic diseases. I now see it in my office every day.

Dr. Eitches: I think of my role as a holistic approach to primary care. I get to learn about my patient's backgrounds, families, hobbies, and values. I understand their health goals and concerns in this context. I do have conventional training as a board-certified MD and run standard tests and prescribe medications when needed. I also have a board certification in integrative holistic medicine, which I lean into, to recommend supplements and refer to complementary healing modalities. With all of my patients, I always address optimizing nutrition, activity, sleep, and mental wellness.

Dr. Eitches: My nutrition plans are evidence-based and customized for each patient's preferences and underlying conditions. For instance, I recommend a plant-based diet for heart disease, diabetes and cancer, but a gluten-free diet for Hashimoto's, or a dairy-free diet for acne, or a low-FODMAP diet for IBS. In all of these cases, I recommend a three-month trial of the diet to see whether we see a difference in their symptoms or labs. I try to balance these recommendations by focusing on the healthful foods to include rather than on what to avoid. We need to be aware that restrictive diets can be isolating and triggering for some people, so there is no one-size-fits-all.

I do think that everybody should eat more greens and fruits and veggies and that nobody should consume dairy. There is great evidence that a whole-food, plant-based diet decreases cholesterol and blood sugar, decreases cancer risk, decreases inflammation and improves bowel regularity. When a patient is ready to try a plant-based lifestyle I am so excited to guide and encourage them on this journey.

Dr. Eitches: Start with adding plants to every meal. Think about the different types of plant foods: Fruits, veggies, greens, legumes, grains, and nuts, and explore all of them. Get excited about a recipe or a farm-share. Some non-vegan foods are simple to swap out such as dairy for plant-based milk and others can be slowly crowded off of the plate.

Dr. Eitches: I recommend that all vegans have their B12 and homocysteine levels checked yearly. Ideally, our B12 levels should be over 400, and homocysteine should be below 8. We should take a B12 supplement, such as a methylcobalamin lozenge or spray to get to these goals. B12 is hugely important for our energy levels, mood, and neurologic function. I often will check omega 3's, vitamin D and iodineas all of these levels tend to be lower in vegans.

Dr. Eitches: There is some meal planning that has to happen around traveling and events, but it's pretty easy to plan ahead. I do make sure to always have vegan cupcakes on hand, either as a mix or in the freezer, so that my kids never feel left out at a birthday party.

Dr. Eitches: I eat plenty of legumes, especially lentils, black beans and edamame. I sometimes add pea protein to my smoothies. I also love (sprouted, organic, non-GMO) tofu and seitan.

Dr. Eitches: I love food, so I can't pick just one. I do love to make a huge green salad and tofu scramble, which I have a few times a week. I live in LA, where it is easy to order amazing vegan food. Some of my favorites are Thai eggplant with brown rice or papaya salad, Ethiopian platters, Japanese ramen and veggie sushi, Indian bharta or bhindi, and Mexican fajitas or burritos.

Dr. Eiches: I would like my life to be a statement of love and compassion and where it isnt, thats where my work lies. -- Ram Dass

Read more:
September is Self Care Month. Here's how to Eat for Wellness - The Beet

How three equine athletes returned from injury to the show ring

At some point in your horse care journey, youve likely ridden a beautiful round, brought your horse in from turnout, or unloaded him from the trailer and realized something was off. Maybe it was a lame step or the slightest bit of swelling but, either way, it prompted a call to your veterinarian. If you were lucky, the root cause was something minor that would resolve with time off and anti-inflammatories. With the more challenging cases, however, you and your veterinarian might have pursued further diagnostics to determine the cause.

After reaching a diagnosis and settling on a treatment plan, you began the arduous process of healing and rehabilitation. This stage can be trying for even the most patient equestrian. But, with a good equine care team and some time, it can be smooth and fruitful.

To see what effective rehabilitation looks like, we found three real-life examples of equine athletes that made full recoveries from their injuries. Well share each ones diagnostic challenges, rehab modalities, and recovery details.

Chanel, a 10-year-old Quarter Horse mare competing in Western pleasure, had been struggling for years with a nagging intermittent left front lameness. Her owner and veterinarian managed this with routine coffin joint corticosteroid injections for about two years. However, the injections ultimately proved to be ineffective at keeping Chanel completely sound and comfortable, so she was referred to Carrie Schlachter, VMD, Dipl. ACVSMR, who founded and designed Circle Oak Equine Sports Medicines rehabilitation and fitness programs and also founded Animals In Motion, a practice that focuses on integrative sports medicine, rehabilitation, and injury prevention.

The case was pretty routine, says Schlachter. We nerve-blocked (used local anesthesia to numb and pinpoint the painful area) her foot, then we X rayed the area, and the X rays showed some mild abnormality in her coffin bone. We recommended an MRI so we could look at the area more deeply.

The MRI showed that Chanel actually had two injuries to her left front foot. The first was mild coffin bone bruising and remodeling in the area we had been looking at radiographically, Schlachter says. But, on the opposite side of the foot, she also had a collateral ligament injury. Collateral ligaments are located on either side of most joints.

This was the aha! moment, she says: Without the MRI I wouldnt have known about the collateral ligament injury so, because the owners were willing to do the MRI, I was not only able to confirm my diagnosis of the bone bruising and remodeling but I was also able to see the reason for it.

Chanel had likely been compensating for the collateral ligament injury by bearing more weight on one side of her foot, creating the bruising in the coffin bone. The injections helped initially because they suffused the area with steroids, reducing inflammation and allowing her to continue working soundly for a brief period.

With a diagnosis in place, Schlachter recommended putting Chanel in a bar shoe to support and stabilize the collateral ligament and the coffin bone. She and her team also injected the coffin joint and the collateral ligament with autologous protein solution (a biologic therapy that stimulates the bodys production of anti-inflammatory mediators and growth factors) and treated the area with extracorporeal shock wave therapy (believed to improve new blood vessel growth, recruit mesenchymal stem cells, and have pain relieving effects).

Schlachter also recommended for Chanel a controlled exercise program, which she modifies to meet the needs of different injuries and disciplines but typically involves:

Two months post-diagnosis, Schlachter reevaluated Chanel. At that point she was 80-90% better, so we allowed her to be walked under saddle for the next two months, she says. When we looked at her again at the four-month mark, she was 100% sound, so we started her on some trot work.

Once she was sound at the canter, Chanel began working back into training. Eight months post-diagnosis she was still sound and back in the show ring. She is now free of bar shoes, and her only maintenance since recovering has been a round of hock and sacroiliac joint injections to manage normal wear and tear.

Chanel was a wonderful patient, Schlachter says. She is the picture perfect example of what a good diagnosis, good treatment, compliant owners, and a well-behaved horse can do.

Melissa King, DVM, PhD, Dipl. ACVSMR, is an associate professor at the Colorado State University (CSU) Veterinary Teaching Hospital, in Fort Collins, where she specializes in equine sports medicine and rehabilitation. King treated JR, a 16-year-old Thoroughbred who had shown as a four-star eventer. From repetitive use in his job, JR developed an insertional lesion in his deep digital flexor tendon (DDFT, which runs from the knee down the back of the leg and around the navicular bone, attaching to the coffin bone) and a second, discrete tear at the pastern level. This article continues in the August 2020 issue of The Horse: Your Guide to Equine Health Care. Subscribe now and get an immediate download of the issue to continue reading. Current magazine subscribers can access the digital edition here.

See original here:
The Journey Back: Three Horses Go From Rehab to Recovery - TheHorse.com

J.D. Prose|Beaver County Times

U.S. Rep. Conor Lamb has co-introduced a trio of bills with three different Republican colleagues to help veterans gain mental-health services and improve government suicide prevention efforts.

In the past week, Lamb, D-17, Mount Lebanon, has teamed with Pennsylvania Rep. Brian Fitzpatrick, R-Bucks County, on the Testing, Researching and Expanding Alternative Treatments (TREAT) Act; Rep. Mike Bost, R-Ill., on the VA Precision Medicine Act and Rep. Jim Banks, R-Ind., on the VA Data Analytics and Technology Assistance (DATA) Act.

We must do more to combat the veteran suicide crisis, said Lamb, a Marine Corps veteran and vice chairman of the House Committee on Veterans Affairs, in a joint statement. Congress needs to give the (Department of Veterans Affairs) every tool possible to meet the mental health challenges facing our veterans before they get to the point of danger.

Lamb added that the work is critical, and it is bipartisan because we all know that one more veteran lost to suicide is one too many.

Fitzpatrick said that "it is imperative that our nations veterans receive access to the highest quality medical testing and holistic treatment options, including for mental health.

Under the TREAT Act, the Department of Veterans Affairs (VA) would be required to create a two-year program to provide complementary and integrative care services for treating post-traumatic stress disorder, depression and anxiety, as well as to conduct a study on treatments such as yoga, meditation, acupuncture, chiropractic care and others that address mental and physical conditions.

The VA Precision Medicine Act would direct the VA to establish the Precision Medicine Initiative for Veterans that Lambs statement said would identify and validate brain and mental health biomarkers among veterans, with specific consideration for depression, anxiety, PTSD, TBI (traumatic brain injuries), and bipolar disorder.

That bill also would have the VA create a robust data privacy and security measures to ensure veterans personal information is kept secure.

The VAs capacity to contract and work with academic and research groups on analyses and data evaluation would be expanded under the DATA Act.

Read the rest here:
Lamb partners with GOP colleagues on three veteran-focused bills - The Times

CoachCare, a virtual health and remote patient monitoring platform for providers and patients across specialties, today announced survey results for over 1,400 patients currently undergoing virtual visits on the CoachCare platform during COVID-19. According to the survey, the patient response to virtual visits was highly positive, with a significant number of patients expecting virtual visits to be a part of their treatment going forward. These findings indicate that clinics and providers must implement a long-term virtual care solution to remain competitive.

CoachCare providesvirtual health and remote patient monitoring servicesto over 3,500 clinics, and approximately 100,000 providers and patients. Earlier this year, as the healthcare industry found itself forced to evolve into a virtual environment practically overnight due to COVID-19, CoachCare sought to understand how patients were reacting to the new reality. The survey revealed that patients were both accepting and optimistic about the changes to their healthcare routines.

Recommended AI News:Litmus and Oden Partner to Offer Complete IIoT Solution for Smart Manufacturing

Our survey shows that although only a small percentage of patients had used virtual video visits prior to COVID-19, they quickly adjusted. Many patients now prefer virtual care or a combination of virtual and in-person care compared to strictly in-person appointments, said CoachCare Marketing Director, Carol Duke, who ran the survey. This is encouraging news for clinics and providers who are worried their patients will resist virtual care, now and in the future.

Providers in the healthcare space have faced unprecedented changes to their businesses and patient programs as they have been forced to look for ways to continue to care for their patients during COVID-19. Part of the challenge is the need to implement new services and technologies for staff and patients to stay safe, while keeping their clinics open. Today, patient services such as remote patient monitoring and secure video visits are a necessity for providers.

Recommended AI News:S&P Global Market Intelligence Becomes Exclusive Provider of Citigroup Aftermarket Research

The CoachCare survey shows that these virtual technologies are beneficial to both the clinic and patient, allowing clinics an acceptable way to monitor and check on their patients at any time between in-person visits, and providing patients with more flexibility, time, and money when it comes to their healthcare journey.

Secure video visits are just the tip of the iceberg here. Duke continued. COVID has brought to the forefront the need for providers to not only visit with their patients remotely but also to fully monitor their conditions and programs from home, 24/7. This is not something that will go away once COVID passes. Patients will expect personalized remote care moving forward.

All of the survey highlights can be seen below:

Title: Patient Response to Virtual Visits Due to COVID-19

Recommended AI News:ZelaaPayAE Partners with Tron to Empower Users with a Dual Chain Solution

Read more:
90% Of Patients Utilizing Virtual Visits; 63% Say They Want to Continue - AiThority

Tom Hanks and his wife, Rita Wilson, were among the earliest celebrities to catch the novel coronavirus. In an interview at the beginning of July, Hanks described how differently COVID-19 had affected each of them in March.

My wife lost her sense of taste and smell, she had severe nausea, she had a much higher fever than I did. I just had crippling body aches, he said. I was very fatigued all the time and I couldnt concentrate on anything for more than about 12 minutes.

Why does COVID-19 present such different symptoms or none at all in different people?

Preexisting conditions can only be part of the story. Hanks is over 60 and is a Type 2 diabetic, putting him in a high-risk group. Nevertheless, he survived his brush with the virus with no pneumonia and apparently without any long-lasting effects. Knowing what causes variation in different patients could help physicians tailor their treatments to individual patients an approach known as precision medicine.

In recent years, a gene-centric approach to precision medicine has been promoted as the future of medicine. It underlies the massive effort funded by the U.S. National Institutes of Health to collect over a million DNA samples under the All of Us initiative that began in 2015.

But the imagined future did not include COVID-19. In the rush to find a COVID-19 vaccine and effective therapies, precision medicine has been insignificant. Why is this? And what are its potential contributions?

We are a physician geneticist and a philosopher of science who began a discussion about the promise and potential pitfalls of precision medicine before the arrival of COVID-19. If precision medicine is the future of medicine, then its application to pandemics generally, and COVID-19 in particular, may yet prove to be highly significant. But its role so far has been limited. Precision medicine must consider more than just genetics. It requires an integrative omic approach that must collect information from multiple sources beyond just genes and at scales ranging from molecules to society.

Inherited diseases such as sickle cell anemia and Tay-Sachs disease follow a predictable pattern. But such direct genetic causes are perhaps the exception rather than the rule when it comes to health outcomes. Some heritable conditions for instance, psoriasis or the many forms of cancer depend on complex combinations of genes, environmental and social factors whose individual contributions to the disease are difficult to isolate. At best, the presence of certain genes constitutes a risk factor in a population but does not fully determine the outcome for an individual person carrying those genes.

The situation becomes yet more complicated for infectious diseases.

Viruses and bacteria have their own genomes that interact in complex ways with the cells in the people they infect. The genome of SARS-CoV-2 underlying COVID-19 has been extensively sequenced. Its mutations are identified and traced worldwide, helping epidemiologists understand the spread of the virus. However, the interactions between SARS-CoV-2 RNA and human DNA, and the effect on people of the viruss mutations, remain unknown.

Tom Hanks and his wife caught the virus and recovered in a matter of weeks. Presumably each was infected over the course of a few minutes of exposure to another infected person, involving cellular mechanisms that operate on a timescale of milliseconds.

But the drama of their illness, and that of the many victims with far worse outcomes, is taking place in the context of a global pandemic that has already lasted months and may continue for years. People will need to adopt changes in their behavior for weeks or months at a time.

What should a precision medicine approach be in a pandemic? The gene-centric vision of precision medicine encourages people to expect individualized gene-targeted fixes. But, genes, behavior and social groups interact over multiple timescales.

To capture all the data needed for such an approach is beyond possibility in the current crisis. A nuanced approach to the COVID-19 pandemic will depend heavily on imprecise population level public health interventions: mask-wearing, social distancing and working from home. Nevertheless, there is an opportunity to begin gathering the kinds of data that would allow for a more comprehensive precision medicine approach one that is fully aware of the complex interactions between genomes and social behavior.

With unlimited resources, a precision medicine approach would begin by analyzing the genomes of a large group of people already known to be exposed to SARS-CoV-2 yet asymptomatic, along with a similar-sized group with identified risk factors who are dying from the disease or are severely ill.

An early study of this kind by Precisionlife Ltd data mined genetic samples of 976 known COVID-19 cases. Of these, 68 high-risk genes were identified as risk factors for poor COVID-19 outcomes, with 17 of them deemed likely to be good targets for drug developments. But, as with all such statistical approaches, the full spectrum of causes underlying their association with the disease is not something the analysis provides. Other studies of this kind are appearing with increasing frequency, but there is no certainty in such fast-moving areas of science. Disentangling all the relevant factors is a process that will take months to years.

To date, precision medicine has proven better suited to inherited diseases and to diseases such as cancer, involving mutations acquired during a persons lifetime, than to infectious diseases. There are examples where susceptibility to infection can be caused by malfunction of unique genes such as the family of inherited immune disorders known as agammaglobulinemia, but these are few and far between.

Many physicians assume that most diseases involve multiple genes and are thus not amenable to a precision approach. In the absence of the kind of information needed for a multi-omic approach, there is a clear challenge and opportunity for precision medicine here: If it is to be the future of medicine, in order to complement and expand our existing knowledge and approaches, it needs to shift from its gene-centric origins toward a broader view that includes variables like proteins and metabolites. It must consider the relationships between genes and their physical manifestations on scales that range from days to decades, and from molecules to the global society.

Read this article:
How to use precision medicine to personalize COVID-19 treatment according to the patient's genes - The Conversation US

Charlotte, NC Quick question: Are you holding your breath right now? If youre anything like the rest of us you probably answered. Yes.

Holding your breath or breathing at a shallower rate when youre using any kind of screen is a Real Thing. It even has a name: Screen apnea. Others have dubbed it email apnea, or, more recently, Zoom apnea, after the online meeting app.

Screen apnea was first brought to attention by Linda Stone, a writer/researcher, and former Apple and Microsoft executive, who noticed that the vast majority of us hold our breath or breathe shallowly while using screens.

And its getting a lot more attention now that COVID-19 has radically changed the workday for millions of Americans who now spend countless hours transfixed by phone and computer screens. Dreaded meetings that at least offered a chance to connect now mean: more screen time.

So, if Zoom leaves you feeling depleted, know youre not alone. Feeling trapped at your desk under the gaze of multiple moving headshotsisanxiety-provoking.

The performative aspect alone maintaining a pleasant facial expression while others speak, planning a thoughtful response, and being the center of unwavering attention while you talk can cause a sense of stage fright. Big hint: Turning off the camera can help.

The short answer is: Yes, according toDr. Russell GreenfieldofNovant Health Integrative Medicine.

Over time, screen apnea can:

Screen apnea alters your bodys delicate balance of gasses like oxygen, nitric oxide, and carbon dioxide, Greenfield said. This can cause inflammation and interfere with your immune systems ability to fight infection.

Not exactly good news during the coronavirus pandemic, when we all want our immune systems functioning like well-oiled machines.

Its pretty safe to assume weallhave screen apnea to some degree, Greenfield said, as we focus on devices and spend less time on the aspects of our lives that enhance a sense of peace and comfort.

By changing our habits around three key contributing factors of screen apnea posture, stress, and the breath itself Greenfield said we can protect our health and simply feel better day-to-day.

Most of us think of ergonomics in relation to back pain or repetitive-stress injuries. But ergonomics also affects our breathing.

For example, when we work on computers,e lean forward, extend our necks and round our shoulders, while compressing the rib cage. Strategies:

Relying more on email and texts robs us of vital information wed normally get at the workplace: facial expressions, body language, and tone of voice. That makes it easier for misunderstandings, frustration, and anger to flare, which leads to more stress and poor breathing a vicious cycle. Greenfields advice:

Breathing is one of the few critical body functions we can control. Thats good news it means we can retrain ourselves to breathe in a healthier manner, Greenfield said.

We tend to think of our bodies as isolated parts and systems lungs, heart, brain but everything is interrelated, Greenfield said. The truth is: Our breath is intimately connected to multiple aspects of our well-being.

The foundation of almost every meditation practice, including mindfulness-based stress reduction (MBSR), breathing slowly and deeply enables us to be fully present, and to offer our complete attention to whatever were engaged in. To breathe better:

Bottom line: Paying just a little more attention to your body, your screen habits, and your breathing can improve your life, safeguard your health, and keep your resilience strong.

Read the original post:
Why Heavy Zoom and Screen Time is Hazardous to your Health - Mint Hill Times

Get to know Cardiologist Dr. Bradley A. Radwaner, who serves patients in New York, New York.

(Spin Digit Editorial):- New York City, Sep 4, 2020 (Issuewire.com)One of New Yorks most highly credentialed and respected cardiologists, Dr. Radwaner is the Founder and Medical Director of The New York Center for the Prevention of Heart Disease. He opened the practice in 1994 with the goal of integrating state-of-the-art techniques with a concierge level of individualized precision medical care.

In his 30+ years of practice, Dr. Radwaner has developed comprehensive individualized programs to prevent heart attacks, strokes, and sudden death; these seamlessly woven into the internal medicine portion of his practice. Patients are given the full time and attention that is needed for diagnosis, treatment, and education.

Alongside his cardiology practice, Dr. Radwaner is the Founder of Elite Veins NY. There, he uses cutting-edge therapeutic methods to treat patients with conditions such as venous insufficiency, spider veins, varicose veins, leg cramps, swelling, and pain, using radiofrequency vein ablation, sclerotherapy, and other minimally invasive treatments. In addition to advanced treatment techniques, he offers free vein consultations.

When he is not seeing his patients at The New York Center for the Prevention of Heart Disease and Elite Veins NY, he teaches medicine at New York University Grossman School of Medicine and is an attending cardiologist at Lenox Hill Hospital.

In the early days of his academic career, Dr. Radwaner obtained his medical degree from Cornell University Medical College in New York in 1980. He completed his residency in internal medicine at Lenox Hill Hospital and his fellowship in cardiology at Columbia University and New York University medical centers. He then spent an additional third year of cardiology training in cardiac catheterization and coronary angioplasty at the New York University Medical Center.

Following his education, Dr. Radwaner served as Associate Director of the Cardiac Catheterization Laboratory at Maimonides Medical Center and as an Assistant Professor of Medicine at Downstate Medical Center in Brooklyn. In Philadelphia, he was on staff at Temple University Hospital as an Assistant Clinical Professor of Medicine.

From 1989 to 1991, he practiced at the Deborah Heart and Lung Center, performing consultative cardiology on referred cardiovascular problems from throughout the East Coast before returning to New York to establish The New York Center for the Prevention of Heart Disease.

Providing an integrative approach to overall health and wellness, Dr. Radwaner is board-certified in internal medicine and cardiovascular disease by the American Board of Internal Medicine (ABIM). The ABIM is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.

In addition to being a Fellow of the American College of Cardiology (FACC) and a Fellow of the American College of Chest Physicians (FCCP), he is a founding member of the National Lipid Association Northeast Chapter, a founding physician of the Society of Computed Tomography (CT), and a lifetime member of Strathmores Whos Who.

A personal advocate and leading authority in the field of preventive cardiology, Dr. Radwaner has conducted several research projects in the treatment of cardiovascular disease. He has also written cardiology research articles and has presented his work at national cardiology meetings.

Cardiology is a branch of medicine that deals with the disorders of the heart, as well as the circulatory system. The field includes medical diagnosis and treatment of congenital heart defects, coronary artery disease, heart failure, valvular heart disease, and electrophysiology. Cardiologists are doctors who diagnose, assess, and treat patients with diseases and defects of the heart and blood vessels (the cardiovascular system).

Among his numerous accolades, Dr. Radwaner has been named Connolly Top Doctors in New York for over 12 years; New York Magazine Top Doctors in Cardiology in New York; Super Docs in New York Times; and Top Physicians in America in Cardiology by the Consumers Research Council of America.

Learn More About Dr. Bradley A. Radwaner:

Through his findatopdoc profile, https://www.findatopdoc.com/doctor/2775903-Bradley-Radwaner-Cardiologist, through The New York Center for the Prevention of Heart Disease, https://www.thenyheartcenter.com/cardiology-staff.html or through Elite Veins NY, https://www.eliteveinsny.com/about

About FindaTopDoc.com

FindaTopDoc is a digital health information company that helps connect patients with local physicians and specialists who accept your insurance. Our goal is to help guide you on your journey towards optimal health by providing you with the know-how to make informed decisions for you and your family.

Source :Bradley A. Radwaner, MD, FACC, FCCP

Originally posted here:
Bradley A. Radwaner, MD, FACC, FCCP, a Cardiologist with The New York Center for the Prevention of Heart Disease / Elite - Spin Digit

If you're clued into the ever-changing world of wellness, you may have noticed that energy healing has been steadily gaining mainstream popularity. Millana Snow, an energy healer and founder of Wellness Official, is excited to see it happen.

Energy healing has its roots in Ayurvedic and traditional Chinese medicine, and it comes in many forms, including Reiki, acupuncture, and crystal healing; you can expect different experiences from different teachers, Snow said. Essentially, it's the act of channeling and changing the energy that runs through your body as a way of healing it.

Snow has developed her own practice, which she calls integrative energy healing. "I liken it to being the opposite of acupuncture," she told POPSUGAR; working from the inside (your emotional, mental, and spiritual states) to affect your physical body. "There are so many different healers who have their own approach, their own unique way of seeing the world," Snow explained. "I wanted to bring those approaches to this work."

So what does it look like when you're trying energy healing for the first time? With Snow, it starts with meditation and breathwork, where you'll consciously change your breathing pattern to alter your mental and physical state. From there, "I start to work on your chakra system, the seven main chakras," Snow explained. This helps to unblock your energy channels and return you to "your natural state of well-being," she said.

The goal of this practice is to "move deeper into the unconscious mind," Snow explained, "looking at how your mental stories and ideas are trapped in that energy, in that emotion, in that physical ailment."

If you're thinking about trying energy healing now, we have good news: you don't have to be in person to do it. Snow has been leading energy healing sessions online for two years through Wellness Official, and said you can still get the benefits without leaving your home. She's even led sessions through Instagram Live.

"You put your headphones in, you lay down, and I start to guide you into a meditation to help you go deeper into your subconscious," Snow said. She then leads clients into breathwork before starting to send energy healing. "It's working off the premise that space and time are illusions," she explained. "Energy doesn't need the containers of physical space. It goes wherever it needs to go." While undergoing distance energy healing, Snow's clients have said it actually feels like she's in the room with them, like they can feel the touch of her hands. "It might sound a little scary," Snow laughed. "I promise you, it's not scary. It's all positive, loving energy."

In Snow's experience, most people don't try energy healing until they're going through a tough or challenging time, whether it's in their job, health, or relationships. "They've kind of hit a wall," she said.

But energy healing can actually benefit anyone, no matter where you are in life. "What I hope for most people is that it doesn't have to get really hard before they come to me," Snow explained. If energy healing or even separate aspects of it, such as breathwork or meditation are part of your normal routine, you'll be more in tune with your body and mind. If something's going wrong in life, you'll be so in touch with yourself that you'll pick up on it sooner and have the strength to make a change. "That's what I ultimately wish for all of my clients," Snow said. "That they get into that practice and they can just have that strength and clarity on their own."

Read the original:
Energy Healing Can Renew Your Mind and Body Here's How It Works and What to Expect - POPSUGAR

The UAB team identified how the poorly understood BIN1 gene might be player in Alzheimers disease.

The neurons in this image are stained blue, indicating the presence of the BIN1 protein. Points of direct interaction between BIN1 and calcium channels are in purple.Researchers at the University of Alabama at Birmingham are on the track of a gene that might play a role in the development of Alzheimers disease. The research team is studying a gene called BIN1, which was first linked to Alzheimers disease in 2009.

In a paper recently published online in eLife, the team shows that BIN1 helps to regulate the activity of neurons. This may be significant, as too much neuronal activity, known as hyperexcitability, is associated with Alzheimers disease. BIN1 becomes the first gene to be linked to hyperexcitability as a driver of Alzheimers disease.

BIN1 was identified as a risk factor for Alzheimers following large scale studies called genome wide association studies, which looked at the genomes of thousands of people with and without Alzheimers disease.

These genetic studies showed that variants of BIN1 were present in many of the study participants who had Alzheimers, said Erik Roberson, M.D., Ph.D., the Rebecca Gale Professor in the Department of Neurology, School of Medicine, and lead author of the study. The problem was that nobody had a clear idea what BIN1 does in the brain.

Using different ways of increasing BIN1 and measuring neuronal activity, members of Robersons lab found that neurons with higher BIN1 levels fired more often and were more prone to hyperexcitability.

We think thats important because hyperexcitability is now recognized as a feature of early Alzheimers, said Roberson, who is director of the UAB Alzheimers Disease Center and the Center for Neurodegeneration and Experimental Therapeutics. The neurons fire too often, which appears to lead to damage.

Prior studies had linked BIN1 to the Tau protein, which has long been associated with Alzheimers as one of the hallmarks of the disease.

Importantly, we found a key role for Tau in the hyperexcitability caused by BIN1, said Yuliya Voskobiynyk, a senior graduate student in Robersons lab who led the work. Reducing Tau made neurons resistant to the effects on BIN1 on neuronal hyperexcitability. Along with BIN1 and Tau, a third factor is involved: channels that allow calcium into the neuron, which are important for neuronal firing. We found that calcium channels form a complex along with BIN1 and Tau, and reducing Tau not only blocked neuronal hyperexcitability, but also reduced the formation of this complex.

Erik Roberson, M.D., Ph.D.Roberson is quick to point out that this research, conducted in animal models and cell cultures, is very preliminary. Tau is a major research focus for investigators worldwide; but the role of BIN1, and its interactions with Tau and calcium channels, is only starting to be explored.

It seems clear that something about this gene has a role to play in Alzheimers, Roberson said. At this point, we dont know if that role is driven by too much BIN1 protein, too little, or by more subtle changes in the type of BIN1 being made in people with Alzheimers disease.

Roberson says next steps will include digging deeper into the genes normal function within the brain, and then working to understand what happens in Alzheimers disease. His lab was already working to develop drugs that would block the binding between Tau and proteins like BIN1 as potential therapies.

This study helps to establish that there is a connection between Tau, BIN1 and calcium channels, Roberson said. But we need to learn more. We need to understand how they bind and how binding affects their function. If we can zero in on the molecular details of these interactions, we may be able to find new targets for intervention.

The research was supported by the National Institutes of Health grants RF1AG059405, R01NS075487, R01MH114990, T32NS095775 and T32NS061788; the

Alzheimers Association; and the Weston Brain Institute.

Co-authors are Jonathan R. Roth, J. Nicholas Cochran, Travis Rush, Jacob S. Mesina, Mohammad Waqas and Rachael Vollmer, of the UAB Center for Neurodegeneration and Experimental Therapeutics, Alzheimers Disease Center and Evelyn McKnight Brain Institute; Nancy V.N. Carullo and Jeremy Day, Ph.D., UAB Department of Neurobiology; and Lori McMahon, Ph.D., UAB Department of Cell, Developmental and Integrative Biology.

The rest is here:
UAB study targets gene associated with Alzheimer's disease - The Mix

Global Nutrigenomics Market was valued US$ XX Mn in 2018 and is expected to reach XX Mn by 2026, at a CAGR of XX % during a forecast period.

Nutrigenomics is a domain of science, which regulates the association between human genome, nutritional diet, and healthcare. It also helps in the understanding about what one intake and how the ample human system responds to the food.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/30470

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

The increasing occurrence of metabolic ailments, the growing overweight population, and rising utilization of nutrigenomics in dermatology are some of the factors behind the global nutrigenomics market. Additionally, increasing healthcare spending and government support for research & development and technology advancement along with increasing demand for advanced diagnostic methods are expected to boost the growth in the global nutrigenomics market. Furthermore, the high cost of the treatment and lack of qualified healthcare service providers & professionals is limiting the growth of the global nutrigenomics market.

The reagents and kits segment is projected to dominate the global nutrigenomics market. The factors, which are responsible for its dominance are growth in clinical laboratories across the globe and the increasing prevalence of chronic diseases like obesity, diabetes, cardiovascular complication, and cancer. Furthermore, the services segment is expected to hold steady growth on account of technical innovations in IT healthcare services and apps. Compulsory generation of Electronic Health Record (EHR) of patients is expected to the adoption of these services, which is expected to increase market demand.

Presently buccal swabs are the most preferred test owing to its quick, non-invasive procedure and less pain related to the sample collection. The consumers indicate a great inclination towards the oral sample collection method owing to its essential advantageous features like quick, ease of collection, pain, and venipuncture associated with sample collection. Researchers are carefully working to address the bacterial contamination issue, which undermines the DNA collected in oral samples.

North America is expected to contribute substantial growth in the global nutrigenomics market share during the forecast period. The significant growth can be credited to the introduction of direct to consumer nutrigenomics supplies and the humungous ingestion of specialized diet and adoption of the latest technologies & biotechnologies in the food sector. Additionally, developed countries like the U.S. and Canada have a huge number of obese patients, who are suffering from lifestyle disorders like diabetes. These factors are expected to increase the need for nutrigenomics in this region. Furthermore, the Asia Pacific regional market is expected to grow at a XX % rate of CAGR in the during the forecast period. The region is expected to witness considerable growth in the global nutrigenomics market owing to increasing demand for functional food and beverages, resulting in an increase in the adoption of the nutrigenomics techniques.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/30470

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding dynamics, structure by analyzing the market segments and, projects the global nutrigenomics market. The report also provides a clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global nutrigenomics market. The report also provides PEST analysis, PORTERs analysis, SWOT analysis to address the question of shareholders in arranging the efforts and investment in the near future to a particular market segment.The Scope of the Report for Global Nutrigenomics Market

Global Nutrigenomics Market,By Products

Reagents & kits ServicesGlobal Nutrigenomics Market,By Techniques

Saliva Buccal swab Blood OthersGlobal Nutrigenomics Market,By Application

Obesity Diabetes Anti-aging Chronic diseasesGlobal Nutrigenomics Market,By Region

North America Europe Asia Pacific Middle East & Africa Latin AmericaKey players are operating in Global Nutrigenomics Market

Koninklijke DSM N.V. BASF SE Danone GeneSmart Unilever Genova Diagnostics Inc. NutriGenomix, Inc. Cell Logic Cura Integrative Medicine Centogene Genomix Nutrition, Inc. Metagenics, Inc. Navigenics XCODE Life Sciences, Pvt. Ltd. WellGen, Inc.

MAJOR TOC OF THE REPORT

Chapter One: Nutrigenomics Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nutrigenomics Market Competition, by Players

Chapter Four: Global Nutrigenomics Market Size by Regions

Chapter Five: North America Nutrigenomics Revenue by Countries

Chapter Six: Europe Nutrigenomics Revenue by Countries

Chapter Seven: Asia-Pacific Nutrigenomics Revenue by Countries

Chapter Eight: South America Nutrigenomics Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nutrigenomics by Countries

Chapter Ten: Global Nutrigenomics Market Segment by Type

Chapter Eleven: Global Nutrigenomics Market Segment by Application

Chapter Twelve: Global Nutrigenomics Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nutrigenomics Market Report at:https://www.maximizemarketresearch.com/market-report/global-nutrigenomics-market/30470/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

See the original post here:
Global Nutrigenomics Market : Global Industry Analysis and Forecast (2019-2026) By Product, Techniques, Applications, and Region - Galus Australis

The U.S. Centers for Disease Control and Prevention did not "backpedal" on the number of deaths caused by Covid-19, reducing the figure from nearly 154,000 to just over 9,000, as social media posts claimed.

The term "Only 6%" trended widely on Twitter over the weekend as supporters of the QAnon conspiracy theory promoted tweets that falsely suggested the CDC had updated its records to show that only 6% of U.S. deaths tied to Covid-19 were legitimate. President Donald Trump was among those who tweeted the information, which was later taken down by Twitter for violating platform rules.

The posts, which received hundreds of thousands of shares online, were based on a regularly updated CDC data table showing underlying conditions for those who died of Covid-19. The conditions included high blood pressure, diabetes and obesity, as well as problems that are caused by Covid-19 itself, such as respiratory failure and pneumonia.

The other 94% list Covid-19 and other conditions together. Among those deaths, there were, on average, 2.6 additional conditions or causes per death, the public health agency said.

As of Aug. 26, the CDC said, there were 161,332 deaths where Covid-19 was listed on the death certificate. Social media users over the weekend posted an older screenshot of the data that showed 153,504 deaths. The posts used the 6% figure to claim the U.S. death toll was much lower - 9,210.

"CDC just backpedaled (quietly) and adjusted the U.S. Covid deaths from 153,504 to 9,210. Admitting that their numbers are so (expletive) that they are off by a whopping 94%," said a post being shared on Facebook Monday.

But such claims misrepresent the data. A death isn't excluded from the Covid-19 tally just because the person was obese or had diabetes or dementia. Someone with heart problems can still be killed by Covid-19, and the death certificate could mention both as contributing.

Experts say it's not surprising that so few people who died from Covid-19 had no underlying conditions listed on their death certificates. It is rare for people not to have multiple medical issues at death.

Also, while death certificates are supposed to list any causes or conditions that contributed, past research has shown that the documents aren't perfect. Doctors might not know - or specify - all the reasons behind a particular death.

More important, the CDC figures show what medical professionals have been saying since the outset of the pandemic - that the virus tends to have a more severe impact on people with underlying conditions.

For example, people died with diabetes not because of it, said Dr. William Schaffner, an infectious-diseases expert at Vanderbilt University.

"If it hadn't been for the Covid virus infection, these people would be living today," he said. "So yes, although they have contributing underlying chronic health factors, it's still the Covid virus that killed them."

View original post here:
CDC has not reduced the death count related to Covid-19 - ETHealthworld.com

The Alliance Review

ALLIANCE University of Mount Union has announced 11 new full-time faculty members for the 2020-2021 academic year.

Toms Barrett joins Mount Union as an assistant professor of exercise, sport and nutrition sciences while currently completing his Ph.D. in neuroscience at Central Michigan University. Prior to that, he earned a Master of Arts in kinesiology and in exercise physiology from Central Michigan University and a Bachelor of Science in sports and exercise science from the University of Limerick in his home country of Ireland.

Dr. Lee Dionne has joined the Department of Political Science and International Studies. He earned a Ph.D. in political science from the University of California-San Diego, a J.D. from the Northwestern University School of Law, a Master of Arts degree from California State University-San Bernardino and a Bachelor of Arts from University of California-Riverside.

Dr. Lynn Dudash has joined the School of Engineering as an assistant professor specializing in biomedical engineering. She earned Ph.D. and Master of Science degrees from Case Western Reserve University and a Bachelor of Science degree in biomedical engineering from the Georgia Institute of Technology.

Arron Foster is a new teaching fellow in the Department of Art and with the institutions Integrative Core program. He earned a Master of Fine Arts degree in printmaking from the University of Georgia and a Bachelor of Fine Arts degree in printmaking and art education from East Carolina University.

Dr. Vahraz Honary also joins the School of Engineering as an assistant professor. He earned a Ph.D. in computer engineering from the University of Nebraska-Lincoln, a Master of Science degree in mobile broadband communication from Lancaster University and a Bachelor of Science degree in electrical and electronic engineering from National University of Guilan in Iran.

Dr. Tim Koba has joined the Department of Business as a visiting assistant professor of sport business. He worked in sport medicine and fitness for 12 years prior to earning his Ph.D. in sport management from the University of South Carolina. He also earned a Master of Science degree in sport management and a Bachelor of Science degree in athletic training from the State University of New York-Cortland.

Dr. Tim Meyers joins Mount Union after 13 successful years at Kent State University. He will lead the Department of Nursing as a professor and chair. He earned a Ph.D. from Kent State University, a Master of Science in Nursing from Clarion University of Pennsylvania and a Bachelor of Science in Nursing from Edinboro University of Pennsylvania.

Dr. Maureen Morton joins the Department of Mathematics as an assistant professor. She earned a Ph.D. in applied mathematics from Michigan State University and a Bachelor of Arts degree in Russian language and literature from the University of Kansas.

Dr. Noriko Okura has joined the Department of World Languages and Cultures and its its Japanese program as a visiting assistant professor. She earned a Doctor of Education degree in leadership and policy studies from Eastern Kentucky University, Master of Arts degrees in Japanese language pedagogy from Columbia University and Mary Baldwin College and a Bachelor of Arts degree from Doshisha Womens College.

Dr. Zhongkun Frankie Ouyang is the final new member of the School of Engineering and joins the institution as an assistant professor of civil engineering. He earned a Ph.D. in geotechnical and geo-environmental engineering and a Master of Science degree in civil engineering from the Georgia Institute of Technology and a Bachelor of Engineering degree in civil engineering from The University of Hong Kong.

Lisa Parnell also joins the Department of Art as an assistant professor. She comes to Mount Union following more than two decades of global industry experience. She earned a Master of Fine Arts in visual communication from Kent State University and a Bachelor of Science form Bournemouth University in the United Kingdom.

Original post:
Mount Union adds 11 to full-time faculty - The-review

The esteemed group of medical professionals bring expertise in cardiovascular medicine, cardiopulmonary exercise, neurology and neuroscience

NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Peloton (NASDAQ: PTON), the world's largest interactive fitness platform, today announced the formation of the Peloton Health and Wellness Advisory Council, which will work closely with the company as it continues to look at how it can positively impact the physical, mental and emotional wellbeing of its community of Members from around the world. Peloton will collaborate with the council, which includes five renowned doctors, researchers and other medical professionals from the fields of cardiovascular medicine, cardiopulmonary exercise, neurology and neuroscience, and draw on their knowledge and expertise to help inform product and content development, community-focused and social impact initiatives, research projects and more.

"We constantly hear from our Members that Peloton has not only profoundly impacted their physical, mental and emotional health, but has also helped them cope with issues ranging from neurodegenerative disease or cancer, to PTSD or post-partum depression," said William Lynch, president, Peloton. "With the addition of this esteemed Health and Wellness Advisory Council, which includes some of the best minds in medicine, we can leverage scientific research and medical expertise to help us better serve our community through our content, products and platform."

The Peloton Health and Wellness Advisory Council includes the following experts:

Cardiovascular MedicineSuzanne Steinbaum, MD:Dr. Suzanne Steinbaum is an attending cardiologist, specializing in prevention. She has recently opened a private practice in New York City, at the Juhi-Ash integrative health center encompassing heart health, wellness and prevention, as well as the effects of stress and inflammation on heart health. She is the founder and President of SRSHeart, a personalized lifestyle management program using anatomy, physiology, functional data, genetics and metabolism, along with technology to reach ultimate cardiovascular health. She has been the Director of Women's Cardiovascular Prevention, Health and Wellness at Mt. Sinai Heart in New York City, after being the Director of Women's Heart Health at Northwell Lenox Hill. Dr. Steinbaum is a Fellow of the American College of Cardiology and the American Heart Association. She is a National Spokesperson for the Go Red for Women campaign and chairperson of the Go Red for Women in New York City. She is on the New York City Board of the American Heart Association and on the Scientific Advisory Board of the Women's Heart Alliance.

NeurologyRichard S. Isaacson, MD:Richard S. Isaacson, M.D. is a Neurologist, clinician and researcher who specializes in Alzheimer's prevention and treatment. He previously served as Associate Professor of Clinical Neurology, Vice Chair of Education, and Education Director of the McKnight Brain Institute in the Department of Neurology at the University of Miami (UM) Miller School of Medicine. Prior to joining UM, he served as Associate Medical Director of the Wien Center for Alzheimer's disease and Memory Disorders at Mount Sinai. Dr. Isaacson specializes in Alzheimer's disease (AD) risk reduction and treatment, mild cognitive impairment due to AD and preclinical AD. His clinical research has shown that individualized clinical management of patients at risk for AD dementia is an important strategy for optimizing cognitive function and reducing risk of dementia. He has also published novel methods on using a precision medicine approach in real-world clinical practice. He has also led the development of Alzheimer's Universe (AlzU.org) a vast online education research portal on AD with results published in the Journal of the Prevention of Alzheimer's disease, Journal of Communication in Healthcare, Alzheimer's & Dementia: Translational Research & Clinical Interventions, and Neurology. With a robust clinical practice and broad background in computer science, m-Health, biotechnology and web-development, Dr. Isaacson is committed to using technology and lifestyle interventions (such as physical exercise and nutrition) to optimize patient care, AD risk assessment and early intervention.

Story continues

Vernon Williams, MD:Vernon Williams, MD is the Founding Director of the Center for Sports Neurology and Pain Medicine at Cedars-Sinai Kerlan-Jobe Institute in Los Angeles, CA. Dr. Williams is a former Commissioner for the California State Athletic Commission and current Chair of Neurological Health for the Commission's Medical Advisory Committee, as well as a former two-term Chair of the American Academy of Neurology Sports Neurology Section. He serves as a neurological medical consultant to local professional sports organizations such as the Los Angeles Rams, Los Angeles Dodgers, Los Angeles Lakers, Los Angeles Kings and Los Angeles Sparks. He also assists local colleges and numerous high school and youth sports/club athletic teams in this capacity. Dr. Williams is a board-certified clinical neurologist with very specialized areas of subspecialty: Sports Neurology and Pain Medicine. He is actively engaged in researching and developing innovative and effective treatments and technologies that help people recognize symptoms of a neurological injury sooner so that the work of treating them can happen faster, and with less potential for permanent damage. He passionately advocates for optimization of Neurological Health across the lifespan for his patients and peak performance clients.

Cardiopulmonary ExerciseAimee M. Layton, PhD:Aimee Layton, PhD is an Assistant Professor of Applied Physiology in Pediatrics in the Division of Pediatric Cardiology and the Director of the Pediatric Cardiopulmonary Exercise Laboratory at Columbia University Medical Center / New York Presbyterian Hospital. Dr. Layton recently joined the pediatric cardiology team after being director of the adult pulmonary exercise laboratory for a decade. This cross discipline experience provides Dr. Layton with knowledge of both how the lungs and the heart respond to exercise and the role of disease and sports in both adults and kids. Dr. Layton's prior research investigated respiratory biomechanics, with publications in both diseased and healthy populations. Her new research focuses on bridging the gap between the lab and the home, in hopes of impacting kids' behavior and relationship with exercise. Dr. Layton is a respected expert in clinical exercise physiology and has lectured internationally on the topic. Beyond her research, Dr. Layton has been performing exercise testing and counseling for both patients with lung disease and patients with heart disease. She plays an important role as one of the lead exercise physiologists for Columbia University Medical Center in testing, exercise counseling and research.

NeuroscienceJay Alberts, PhD:As a Cleveland Clinic Scientist, Ph.D., Jay Alberts' research is aimed at understanding the structure-function relationships within the central nervous system and evaluating the impact of behavioral and surgical interventions to improve motor and non-motor function in Parkinson's disease, stroke, Alzheimer's and other neurological populations. Human studies are currently ongoing to address these basic and translational research questions. Dr. Alberts is developing and validating new methods of using exercise and augmented and virtual reality to engage patient populations remotely. He is currently leading two multi-site clinical trials investigating the role of exercise in slowing the progression of Parkinson's disease. Dr. Alberts has led multiple successful technology initiatives aimed at better understanding patient symptoms and communicating these symptoms to providers. He is currently building AR and VR applications as prescriptive digital therapeutic systems for neurological patients. To date, Dr. Alberts has written 100 peer reviewed articles, has had uninterrupted extramural funding since 1999 and holds 10 patents.

For more information about Peloton or the Peloton Health and Wellness Advisory Council, please visit http://www.blog.onepeloton.com.

About PelotonPeloton is the largest interactive fitness platform in the world with a loyal community of more than 2.6 million Members. The company pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its Members anytime, anywhere. Peloton makes fitness entertaining, approachable, effective, and convenient, while fostering social connections that encourage its Members to be the best versions of themselves. An innovator at the nexus of fitness, technology, and media, Peloton has reinvented the fitness industry by developing a first-of-its-kind subscription platform that seamlessly combines the best equipment, proprietary networked software, and world-class streaming digital fitness and wellness content, creating a product that its Members love. The brand's immersive content is accessible through the Peloton Bike, Peloton Tread, and Peloton App, which allows access to a full slate of fitness classes across disciplines, on any iOS or Android device, Apple TV, Fire TV, Roku TVs, and Chromecast and Android TV. Founded in 2012 and headquartered in New York City, Peloton has a growing number of retail showrooms across the US, UK, Canada and Germany. For more information, visit http://www.onepeloton.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/peloton-introduces-its-first-ever-health-and-wellness-advisory-council-301122024.html

SOURCE Peloton

Read the rest here:
Peloton Introduces Its First-Ever Health And Wellness Advisory Council - Yahoo Finance

MediSpin XL high-volume industrial electrospinning platform for both medical devices and new drug delivery applications

WAALRE, The Netherlands, September 03, 2020 / B3C newswire / -- IME Medical Electrospinning, a global leader in electrospun medical devices and regenerative medicine, today announced it has successfully raised 3 million in equity financing and debt from existing shareholder TIIN Capital, new investors Borski Fund and Lumana Invest, and from Rabobank Region Eindhoven.

In 2019 IME launched the MediSpin XL production platform for large-scale industrial manufacturing of reproducible and scalable electrospun nanofiber-based scaffolds for Class I, II and III medical devices, marking a global breakthrough in the controlled large-scale production of batch-consistent, high-quality end-products in volume. To be able to manage the electrospinning control parameters unlocks its full potential for industrial medical applications.

MediSpin XL creates nanometer solutions that mimic the natural extracellular matrix in the human body. Human cells recognize and infiltrate these scaffolds, encouraging quick and efficient tissue integration, resulting in natural tissue restoration while minimizing medical complications.

The vast array of innovative applications include fully bioresorbable stents, heart valves, nanofibrous meshes and many other new devices for a.o. local drug delivery, implantables and tissue engineering.

Judith Heikoop, Managing Director of IME Medical Electrospinning, says: The additional financing and support of new shareholders Borski Fund, Lumana Invest and existing shareholder TIIN Capital will enable us to further strengthen our MediSpin XL electropinning platform and industrial production capabilities for medical devices and drug delivery applications. Combining our state of the art production platform with our broadened focus, underpins our strong belief in the strategic goal of becoming the leader in large-scale production of both medical devices and drug delivery solutions. Now we can jointly develop other breakthrough medical solutions with our pharma partners and expand our operations. The support of both our existing and new investors fills me with pride and shows that they recognize the large value-adding component of our game-changing capabilities.

Ramon Solberg, Founder and together with Judith Heikoop, Managing Director of IME Medical Electrospinning, adds: This new successful financing round enables us to further capitalize on our scientific and technical findings over the past decade, growing our product portfolio from regenerative medtech solutions to the even broader and promising global market for targeted drug delivery solutions.

About Medical ElectrospinningApplying specific polymers, IMEs advanced equipment creates fiber-based medical device solutions that mimic the natural human extracellular matrix in nanometer and micrometer format for implants and membranes in the human body. Human cells recognize this artificial matrix (scaffold) as the bodys own facilitating the repair of the damaged tissue for heart valves, blood vessels, nerves, tendons, skin and bone etc. This is in contrast to implants and membranes of traditional structures, which are seen as foreign and therefore can lead to scar tissue or rejection phenomena. The MediSpin XL platform has been developed specifically for MedTech industrial manufacturing of medical devices and is now also suitable for pharmaceutical drug delivery applicaitons and ensures the firm control of the crucial parameters of the electrospinning process, leading to identical and consistent end-products.

About Borski FundDutch Borski Fund believes in diversity, gender equality and fair opportunities. It invests in female entrepreneurs because it wants to build good companies with them, because their talent needs to be better utilized, because Borski Fund is their natural partner, because is has the network that matters to them. Because it is important that innovation is stimulated by female entrepreneurs.

About Lumana InvestDutch Lumana is an investment company founded by entrepreneurs. Lumana Invest stands for committed stakeholdership supporting management in strategic issues. With an investment horizon for an indefinite period, Lumana has a unique investment approach. In addition, the fund managers responsible for entering into and supervising participations are also founders and co-shareholders of Lumana. Lumana prefers to invest in start-ups in new markets and new techniques. Exploring boundaries with management and, if possible, pushing them further. Forward-looking and with the ambition to permanently change the future. "Lumanai" has been freely translated from Samoan meaning future.

About TIIN Capital TIIN Capital is a Naarden, the Netherlands, based fund manager and uses a network of approximately 1.000 angel investors. Entrepreneurship, knowledge of the market, technology (from the network) and capital are of great added value for the investments. As entrepreneurial investors, TIIN Capital accelerates growth-oriented companies with active growth and buy & build strategies, where innovative entrepreneurship is central to be able to take the next step.

About IME Medical ElectrospinningFor over ten years, IME Medical Electrospinning has been a leading player in the field of developing and implementing electrospinning processes and equipment for the manufacturing of medical devices for (regenerative) medicine and drug delivery. Electrospinning is a flexible process for producing extremely thin fibers and structures that have excellent properties to help regenerate human tissue. IME Medical Electrospinning has developed an unique set of innovations in electrospinning technology for the reproducible and scalable production of electrospun material under tightly controlled conditions required for the MedTech and Pharma market. Customers and scientific partners include the MedTech and Pharma industry, scientists and health institutions.

Contacts

IME Medical Electrospinning, Waalre, The NetherlandsJudith Heikoop M.Sc. Ph.D.+31 40 28 27 956This email address is being protected from spambots. You need JavaScript enabled to view it.

For mediaLifeSpring Life Sciences Communication, AmsterdamLon Melens+31 6 538 16 427This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords: Humans; Nanofibers; Equipment and Supplies; Drug Delivery Systems; Biomimetics; Extracellular Matrix; Capital Financing; Industry; Tissue Engineering; Heart Valves; Drug Delivery Systems; Stents

Published by B3C newswire

Read the original post:
IME Medical Electrospinning Secured 3 Million in New Financing From Dutch VCs Borski Fund, Lumana Invest, TIIN Capital and From Rabobank to Further...

BASKING RIDGE, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the Advanced Therapies Congress & Expo being held virtually September 8-11, 2020.

Title: Repair of the microcirculation reverses ischemic tissue damagePresenter: Douglas W. Losordo, M.D., EVP, Global Head of R&D and Chief Medical OfficerTrack: Stem Cells and Regenerative MedicineDate/Time: Wednesday, September 9, 2020 at 12:00 p.m. (BST)

Title: Roundtable discussion: Development of regenerative medicines for cardiovascular indicationsPresenter: David J. Mazzo, Ph.D., President and Chief Executive OfficerTrack: Stem Cells and Regenerative MedicineDate/Time: Wednesday, September 9, 2020 at 4:00 p.m. (BST)

Additional information can be found on the conference website.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Companys current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming weeks as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (CLI) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (CMD); and CLBS14, a Regenerative Medicine Advanced Therapy (RMAT) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the FDA) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (NORDA). For more information on the company, please visit http://www.caladrius.com.

Contact:

Investors:Caladrius Biosciences, Inc.John MendittoVice President, Investor Relations and Corporate CommunicationsPhone:+1-908-842-0084Email:jmenditto@caladrius.comMedia:W2O GroupChristiana PascalePhone: +1-212-257-6722Email:cpascale@w2ogroup.com

Follow this link:
Caladrius Biosciences to Participate in the Advanced Therapies Congress & Expo 2020 - Yahoo Finance

DUBLIN, Sept. 2, 2020 /PRNewswire/ -- The "Global Cord Blood Banking Industry Report 2020" report has been added to ResearchAndMarkets.com's offering.

This report presents the number of cord blood units stored in inventory by the largest cord blood banks worldwide and the number of cord blood units (CBUs) released by registries across the world for hematopoietic stem cell (HSC) transplantation. Although cord blood is now used to treat more than 80 different diseases, this number could substantially expand if applications related to regenerative medicine start receiving approvals in major healthcare markets worldwide.

From the early 1900s through the mid-2000s, the global cord blood banking industry expanded rapidly, with companies opening for business in all major markets worldwide. From 2005 to 2010, the market reached saturation and stabilized.

Then, from 2010 to 2020, the market began to aggressively consolidate. This has created both serious threats and unique opportunities within the industry.

Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation. There are also emerging opportunities for the industry, such as accelerated regulatory pathways for cell therapies in leading healthcare markets worldwide and expanding applications for cell-based therapies. In particular, MSCs from cord tissue (and other sources) are showing intriguing promise in the treatment and management of COVID-19.

Cord Blood Industry Trends

Within recent years, new themes have been impacting the industry, including the pairing of stem cell storage services with genetic and genomic testing services, as well as reproductive health services. Cord blood banks are diversifying into new types of stem cell storage, including umbilical cord tissue storage, placental blood and tissue, amniotic fluid and tissue, and dental pulp. Cord blood banks are also investigating means of becoming integrated therapeutic companies. With hundreds of companies offering cord blood banking services worldwide, maturation of the market means that each company is fighting harder for market share.

Growing numbers of investors are also entering the marketplace, with M&A activity accelerating in the U.S. and abroad. Holding companies are emerging as a global theme, allowing for increased operational efficiency and economy of scale. Cryoholdco has established itself as the market leader within Latin America. Created in 2015, Cryoholdco is a holding company that will control nearly 270,000 stem cell units by the end of 2020. It now owns a half dozen cord blood banks, as well as a dental stem cell storage company.

Globally, networks of cord blood banks have become commonplace, with Sanpower Group establishing its dominance in Asia. Although Sanpower has been quiet about its operations, it holds 4 licenses out of only 7 issued provincial-level cord blood bank licenses in China. It has reserved over 900,000 cord blood samples in China, and its reserves amount to over 1.2 million units when Cordlife' reserves within Southeast Asian countries are included. This positions Sanpower Group and it's subsidiary Nanjing Cenbest as the world's largest cord blood banking operator not only in China and Southeast Asia but in the world.

The number of cord blood banks in Europe has dropped by more than one-third over the past ten years, from approximately 150 to under 100. The industry leaders in this market segment include FamiCord Group, who has executed a dozen M&A transactions, and Vita34, who has executed approximately a half dozen. Stemlab, the largest cord blood bank in Portugal, also executed three acquisition deals prior to being acquired by FamiCord. FamiCord is now the leading stem cell bank in Europe and one of the largest worldwide.

Cord Blood Expansion Technologies

Because cord blood utilization is largely limited to use in pediatric patients, growing investment is flowing into ex vivo cord blood expansion technologies. If successful, this technology could greatly expand the market potential for cord blood, encouraging its use within new markets, such as regenerative medicine, aging, and augmented immunity.

Key strategies being explored for this purpose include:

Currently, Gamida Cell, Nohla Therapeutics, Excellthera, and Magenta Therapeutics have ex vivo cord blood expansion products proceeding through clinical trials. Growing numbers of investors have also entered the cord blood banking marketplace, led by groups such as GI Partners, ABS Capital Partners & HLM Management, KKR & Company, Bay City Capital, GTCR, LLC, and Excalibur.

Cord Blood Banking by Region

Within the United States, most of the market share is controlled by three major players: Cord Blood Registry (CBR), Cryo-Cell, and ViaCord. CBR has been traded twice, once in 2015 to AMAG Pharmaceuticals for $700 million and again in 2018 to GI Partners for $530 million. CBR also bought Natera's Evercord Cord Blood Banking business in September 2019. In total, CBR controls over 900,000 cord blood and tissue samples, making it one of the largest cord blood banks worldwide.

In China, the government controls the industry by authorizing only one cord blood bank to operate within each province, and official government support, authorization, and permits are required. Importantly, the Chinese government announced in late 2019 that it will be issuing new licenses for the first time, expanding from the current 7 licensed regions for cord blood banking to up to 19 regions, including Beijing.

In Italy and France, it is illegal to privately store one's cord blood, which has fully eliminated the potential for a private market to exist within the region. In Ecuador, the government created the first public cord blood bank and instituted laws such that private cord blood banks cannot approach women about private cord blood banking options during the first six months of pregnancy. This created a crisis for private banks, forcing most out of business.

Recently, India's Central Drugs Standard Control Organization (CDSCO) restricted commercial banking of stem cells from most biological materials, including cord tissue, placenta, and dental pulp stem cells - leaving only umbilical cord blood banking as permitted and licensed within the country.

While market factors vary by geography, it is crucial to have a global understanding of the industry, because research advances, clinical trial findings, and technology advances do not know international boundaries. The cord blood market is global in nature and understanding dynamics within your region is not sufficient for making strategic, informed, and profitable decisions.

Overall, the report provides the reader with the following details and answers the following questions:

1. Number of cord blood units cryopreserved in public and private cord blood banks globally2. Number of hematopoietic stem cell transplants (HSCTs) globally using cord blood cells3. Utilization of cord blood cells in clinical trials for developing regenerative medicines4. The decline of the utilization of cord blood cells in HSC transplantations since 20055. Emerging technologies to influence the financial sustainability of public cord blood banks6. The future scope for companion products from cord blood7. The changing landscape of cord blood cell banking market8. Extension of services by cord blood banks9. Types of cord blood banks10. The economic model of public cord blood banks11. Cost analysis for public cord blood banks12. The economic model of private cord blood banks13. Cost analysis for private cord blood banks14. Profit margins for private cord blood banks15. Pricing for processing and storage in private banks16. Rate per cord blood unit in the U.S. and Europe17. Indications for the use of cord blood-derived HSCs for transplantations18. Diseases targeted by cord blood-derived MSCs in regenerative medicine19. Cord blood processing technologies20. Number of clinical trials, number of published scientific papers and NIH funding for cord blood research21. Transplantation data from different cord blood registries

Key questions answered in this report are:

1. What are the strategies being considered for improving the financial stability of public cord blood banks?2. What are the companion products proposed to be developed from cord blood?3. How much is being spent on processing and storing a unit of cord blood?4. How much does a unit of cryopreserved cord blood unit fetch on release?5. Why do most public cord blood banks incur a loss?6. What is the net profit margin for a private cord blood bank?7. What are the prices for processing and storage of cord blood in private cord blood banks?8. What are the rates per cord blood units in the U.S. and Europe?9. What are the revenues from cord blood sales for major cord blood banks?10. Which are the different accreditation systems for cord blood banks?11. What are the comparative merits of the various cord blood processing technologies?12. What is to be done to increase the rate of utilization of cord blood cells in transplantations?13. Which TNC counts are preferred for transplantation?14. What is the number of registered clinical trials using cord blood and cord tissue?15. How many clinical trials are involved in studying the expansion of cord blood cells in the laboratory?16. How many matching and mismatching transplantations using cord blood units are performed on an annual basis?17. What is the share of cord blood cells used for transplantation from 2000 to 2020?18. What is the likelihood of finding a matching allogeneic cord blood unit by ethnicity?19. Which are the top ten countries for donating cord blood?20. What are the diseases targeted by cord blood-derived MSCs within clinical trials?

Key Topics Covered

1. REPORT OVERVIEW1.1 Statement of the Report1.2 Executive Summary1.3 Introduction1.3.1 Cord Blood: An Alternative Source for HPSCs1.3.2 Utilization of Cord Blood Cells in Clinical Trials1.3.3 The Struggle of Cord Blood Banks1.3.4 Emerging Technologies to Influence Financial Sustainability of Banks1.3.4.1 Other Opportunities to Improve Financial Stability1.3.4.2 Scope for Companion Products1.3.5 Changing Landscape of Cord Blood Cell Banking Market1.3.6 Extension of Services by Cord Blood Banks

2. CORD BLOOD & CORD BLOOD BANKING: AN OVERVIEW2.1 Cord Blood Banking (Stem Cell Banking)2.1.1 Public Cord Blood Banks2.1.1.1 Economic Model of Public Cord Blood Banks2.1.1.2 Cost Analysis for Public Banks2.1.1.3 Relationship between Costs and Release Rates2.1.2 Private Cord Blood Banks2.1.2.1 Cost Analysis for Private Cord Blood Banks2.1.2.2 Economic Model of Private Banks2.1.3 Hybrid Cord Blood Banks2.2 Globally Known Cord Blood Banks2.2.1 Comparing Cord Blood Banks2.2.2 Cord Blood Banks in the U.S.2.2.3 Proportion of Public, Private and Hybrid Banks2.3 Percent Share of Parents of Newborns Storing Cord Blood by Country/Region2.4 Pricing for Processing and Storage in Commercial Banks2.4.1 Rate per Cord Blood Unit in the U.S. and Europe2.5 Cord Blood Revenues for Major Cord Blood Banks

3. CORD BLOOD BANK ACCREDITATIONS3.1 American Association of Blood Banks (AABB)3.2 Foundation for the Accreditation of Cellular Therapy (FACT)3.3 FDA Registration3.4 FDA Biologics License Application (BLA) License3.5 Investigational New Drug (IND) for Cord Blood3.6 Human Tissue Authority (HTA)3.7 Therapeutic Goods Act (TGA) in Australia3.8 International NetCord Foundation3.9 AABB Accredited Cord Blood Facilities3.10 FACT Accreditation for Cord Blood Banks

4. APPLICATIONS OF CORD BLOOD CELLS4.1 Hematopoietic Stem Cell Transplantations with Cord Blood Cells4.2 Cord Cells in Regenerative Medicine

5. CORD BLOOD PROCESSING TECHNOLOGIES5.1 The Process of Separation5.1.1 PrepaCyte-CB5.1.2 Advantages of PrepaCyte-CB5.1.3 Treatment Outcomes with PrepaCyte-CB5.1.4 Hetastarch (HES)5.1.5 AutoXpress (AXP)5.1.6 SEPAX5.1.7 Plasma Depletion Method (MaxCell Process)5.1.8 Density Gradient Method5.2 Comparative Merits of Different Processing Methods5.2.1 Early Stage HSC Recovery by Technologies5.2.2 Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood5.2.3 Late Stage Recovery of HSCs from Cord Blood5.3 HSC (CD45+) Recovery5.4 Days to Neutrophil Engraftment by Technology5.5 Anticoagulants used in Cord Blood Processing5.5.1 Type of Anticoagulant and Cell Recovery Volume5.5.2 Percent Cell Recovery by Sample Size5.5.3 TNC Viability by Time Taken for Transport and Type of Anticoagulant5.6 Cryopreservation of Cord Blood Cells5.7 Bioprocessing of Umbilical Cord Tissue (UCT)5.8 A Proposal to Improve the Utilization Rate of Banked Cord Blood

6. CORD BLOOD CLINICAL TRIALS, SCIENTIFIC PUBLICATIONS & NIH FUNDING6.1 Cord Blood Cells for Research6.2 Cord Blood Cells for Clinical Trials6.2.1 Number of Clinical Trials involving Cord Blood Cells6.2.2 Number of Clinical Trials using Cord Blood Cells by Geography6.2.3 Number of Clinical Trials by Study Type6.2.4 Number of Clinical Trials by Study Phase6.2.5 Number of Clinical Trials by Funder Type6.2.6 Clinical Trials Addressing Indications in Children6.2.7 Select Three Clinical Trials Involving Children6.2.7.1 Sensorineural Hearing Loss (NCT02038972)6.2.7.2 Autism Spectrum (NCT02847182)6.2.7.3 Cerebral Palsy (NCT01147653)6.2.8 Clinical Trials for Neurological Diseases using Cord Blood and Cord Tissue6.2.9 UCB for Diabetes6.2.10 UCB in Cardiovascular Clinical Trials6.2.11 Cord Blood Cells for Auto-Immune Diseases in Clinical Trials6.2.12 Cord Tissue Cells for Orthopedic Disorders in Clinical Trials6.2.13 Cord Blood Cells for Other Indications in Clinical Trials6.3 Major Diseases Addressed by Cord Blood Cells in Clinical Trials6.4 Clinical Trials using Cord Tissue-Derived MSCs6.5 Ongoing Clinical Trials using Cord Tissue6.5.1 Cord Tissue-Based Clinical Trials by Geography6.5.2 Cord Tissue-Based Clinical Trials by Phase6.5.3 Cord Tissue-Based Clinical Trials by Sponsor Types6.5.4 Companies Sponsoring in Trials using Cord Tissue-Derived MSCs6.6 Wharton's Jelly-Derived MSCs in Clinical Trials6.6.1 Wharton's Jelly-Based Clinical Trials by Phase6.6.2 Companies Sponsoring Wharton's Jelly-Based Clinical Trials6.7 Clinical Trials Involving Cord Blood Expansion Studies6.7.1 Safe and Feasible Expansion Protocols6.7.2 List of Clinical Trials involved in the Expansion of Cord Blood HSCs6.7.3 Expansion Technologies6.8 Scientific Publications on Cord Blood6.9 Scientific Publications on Cord Tissue6.10 Scientific Publications on Wharton's Jelly-Derived MSCs6.11 Published Scientific Papers on Cord Blood Cell Expansion6.12 NIH Funding for Cord Blood Research

7. PARENT'S AWARENESS AND ATTITUDE TOWARDS CORD BLOOD BANKING7.1 Undecided Expectant Parents7.2 The Familiar Cord Blood Banks Known by the Expectant Parents7.3 Factors Influencing the Choice of a Cord Blood Bank

8. CORD BLOOD: AS A TRANSPLANTATION MEDICINE8.1 Comparisons of Cord Blood to other Allograft Sources8.1.1 Major Indications for HCTs in the U.S.8.1.2 Trend in Allogeneic HCT in the U.S. by Recipient Age8.1.3 Trends in Autologous HCT in the U.S. by Recipient Age8.2 HCTs by Cell Source in Adult Patients8.2.1 Transplants by Cell Source in Pediatric Patients8.3 Allogeneic HCTs by Cell Source8.3.1 Unrelated Donor Allogeneic HCTs in Patients &lessThan;18 Years8.4 Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity8.4.1 Likelihood of Finding an Unrelated Cord Blood Unit for Patients &lessThan;20 Years8.5 Odds of using a Baby's Cord Blood8.6 Cord Blood Utilization Trends8.7 Number of Cord Blood Donors Worldwide8.7.1 Number of CBUs Stored Worldwide8.7.2 Cord Blood Donors by Geography8.7.2.1 Cord Blood Units Stored in Different Geographies8.7.2.2 Number of Donors by HLA Typing8.7.3 Searches Made by Transplant Patients for Donors/CBUs8.7.4 Types of CBU Shipments (Single/Double/Multi)8.7.5 TNC Count of CBUs Shipped for Children and Adult Patients8.7.6 Shipment of Multiple CBUs8.7.7 Percent Supply of CBUs for National and International Patients8.7.8 Decreasing Number of CBU Utilization8.8 Top Ten Countries in Cord Blood Donation8.8.1 HLA Typed CBUs by Continent8.8.2 Percentage TNC of Banked CBUs8.8.3 Total Number of CBUs, HLA-Typed Units by Country8.9 Cord Blood Export/Import by the E.U. Member States8.9.1 Number of Donors and CBUs in Europe8.9.2 Number of Exports/Imports of CBUs in E.U.8.10 Global Exchange of Cord Blood Units

9. CORD BLOOD CELLS AS THERAPEUTIC CELL PRODUCTS IN CELL THERAPY9.1 MSCs from Cord Blood and Cord Tissue9.1.1 Potential Neurological Applications of Cord Blood-Derived Cells9.1.2 Cord Tissue-Derived MSCs for Therapeutic use9.1.2.1 Indications Targeted by UCT-MSCs in Clinical Trials9.2 Current Consumption of Cord Blood Units by Clinical Trials9.3 Select Cord Blood Stem Cell Treatments in Clinical Trials9.3.1 Acquired Hearing Loss (NCT02038972)9.3.2 Autism (NCT02847182)9.3.3 Cerebral Palsy (NCT03087110)9.3.4 Hypoplastic Left Heart Syndrome (NCT01856049)9.3.5 Type 1 Diabetes (NCT00989547)9.3.6 Psoriasis (NCT03765957)9.3.7 Parkinson's Disease (NCT03550183)9.3.8 Signs of Aging (NCT04174898)9.3.9 Stroke (NCT02433509)9.3.10 Traumatic Brain Injury (NCT01451528)

10. MARKET ANALYSIS10.1 Public vs. Private Cord Blood Banking Market10.2 Cord Blood Banking Market by Indication

11. PROFILES OF SELECT CORD BLOOD BANKS11.1 AllCells11.1.1 Whole Blood11.1.2 Leukopak11.1.3 Mobilized Leukopak11.1.4 Bone Marrow11.1.5 Cord Blood11.2 AlphaCord LLC11.2.1 NextGen Collection System11.3 Americord Registry, Inc.11.3.1 Cord Blood 2.011.3.2 Cord Tissue11.3.3 Placental Tissue 2.011.4 Be The Match11.4.1 Hub of Transplant Network11.4.2 Partners of Be The Match11.4.3 Allogeneic Cell Sources in Be The Match Registry11.4.4 Likelihood of a Matched Donor on Be The Match by Ethnic Background11.5 Biocell Center Corporation11.5.1 Chorionic villi after Delivery11.5.2 Amniotic Fluid and Chorionic Villi during Pregnancy11.6 BioEden Group, Inc.11.6.1 Differences between Tooth Cells and Umbilical Cord Cells11.7 Biovault Family11.7.1 Personalized Cord Blood Processing11.8 Cell Care11.9 Cells4Life Group, LLP11.9.1 Cells4Life's pricing11.9.2 TotiCyte Technology11.9.3 Cord Blood Releases11.10 Cell-Save11.11 Center for International Blood and Marrow Transplant Research (CIBMTR)11.11.1 Global Collaboration11.11.2 Scientific Working Committees11.11.3 Medicare Clinical Trials and Studies11.11.4 Cellular Therapy11.12 Crio-Cell International, Inc.11.12.1 Advanced Collection Kit11.12.2 Prepacyte-CB11.12.3 Crio-Cell International's Pricing11.12.4 Revenue for Crio-Cell International11.13 Cord Blood Center Group11.13.1 Cord Blood Units Released11.14 Cordlife Group, Ltd.11.14.1 Cordlife's Cord Blood Release Track Record11.15 Core23 Biobank11.16 Cord Blood Registry (CBR)11.17 CordVida11.18 Crioestaminal11.18.1 Cord Blood Transplantation in Portugal11.19 Cryo-Cell International, Inc.11.19.1 Processing Method11.19.2 Financial Results of the Company11.20 CryoHoldco11.21 Cryoviva Biotech Pvt. Ltd11.22 European Society for Blood and Bone Marrow Transplantation (EBMT)11.22.1 EBMT Transplant Activity11.23 FamiCord Group11.24 GeneCell International11.25 Global Cord Blood Corporation11.25.1 The Company's Business11.26 HealthBaby Hong Kong11.26.1 BioArchive System Service Plan11.26.2 MVE Liquid Nitrogen System11.27 HEMAFUND11.28 Insception Lifebank11.29 LifebankUSA11.29.1 Placental Banking11.30 LifeCell International Pvt. Ltd.11.31 MiracleCord, Inc.11.32 Maze Cord Blood Laboratories11.33 New England Cord Blood Bank, Inc.11.34 New York Cord Blood Center (NYBC)11.34.1 Products11.34.2 Laboratory Services11.35 PacifiCord11.35.1 FDA-Approved Sterile Collection Bags11.35.2 AXP Processing System11.35.3 BioArchive System11.36 ReeLabs Pvt. Ltd.11.37 Smart Cells International, Ltd.11.38 Stem Cell Cryobank11.39 StemCyte, Inc.11.39.1 StemCyte Sponsored Clinical Trials11.39.1.1 Spinal Cord Injury Phase II11.39.1.2 Other Trials11.40 Transcell Biolife11.40.1 ScellCare11.40.2 ToothScell11.41 ViaCord11.42 Vita 34 AG11.43 World Marrow Donor Association (WMDA)11.43.1 Search & Match Service11.44 Worldwide Network for Blood & Marrow Transplantation (WBMT)

For more information about this report visit https://www.researchandmarkets.com/r/7bm9lx

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Originally posted here:
Global Cord Blood Banking Market 2020 with Analysis of 44 Industry Players - PRNewswire

Gene therapy generally relies on viruses, such as adeno-associated virus (AAV), to deliver genes into a cell. In case of CRISPR-based gene therapies, molecular scissors can then snip out a defective gene, add in a missing sequence or enact a temporary change in its expression, but the bodys immune response to AAV can thwart the whole endeavor.

To overcome that obstacle, researchers at the University of Pittsburgh created a system that uses CRISPR in a different way. Their system briefly suppresses genes that are related to AAV antibody production so the virus can deliver its cargo unimpeded. These results published today in Nature Cell Biology.

Many clinical trials fail because of the immune response against AAV gene therapy, said study co-senior author Samira Kiani, associate professor of pathology in Pitt's School of Medicine and member of the Pittsburgh Liver Research Center (PLRC) and McGowan Institute for Regenerative Medicine. And then you cant readminister the shot because people have developed immunity.

So Kiani and her long-time collaborator Mo Ebrahimkhani, associate professor of pathology at Pitt, member of PLRC and the McGowan Institute, set out to modify gene expression related to the bodys immune response to AAV. But this gene is important for normal immune function, so the researchers didnt want to shut it down forever, just tamp it down momentarily.

Since CRISPR is such a convenient system for editing the genome, the pair figured they would put it to use for altering the master switches that orchestrate genes involved in immune response.

Were hitting two birds with one stone, said Ebrahimkhani. You can use CRISPR to do your gene therapy, and you can also use CRISPR to control the immune response.

When the researchers treated mice with their CRISPR-controlled immune suppression system and then exposed them to AAV again, the animals didnt make more antibodies against the virus. These animals were more receptive to subsequent AAV-delivered gene therapy compared to controls.

Beyond gene therapy, the study also shows that CRISPR-based immune suppression can prevent or treat sepsis in mice, highlighting the potential for this tool to be broadly useful for a range of inflammatory conditions, including cytokine storm and acute respiratory distress syndrome, both of which can crop up with COVID-19, though more studies are needed to engineer safety features.

The main goal of this study was to develop CRISPR-based tools for inflammatory conditions, said study lead author Farzaneh Moghadam, a PhDstudent in Kianis lab. But when we looked at bone marrow samples, we saw that the group treated with our tool showed a lower immune response to AAV compared to the control group. That was very interesting, so we started exploring how this tool contributes to antibody formation against AAV and could potentially address safety and efficacy concerns with gene therapy trials.

Kiani co-founded SafeGen Therapeutics with the goal of bringing this technology to the clinic.

This study was supported by National Institute of Biomedical Imaging and Bioengineering, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, and a DARPA Young Faculty Award.

Additional authors on the study include graduate student Ryan LeGraw and researcher Jeremy Velazquez from Pitt.

See original here:
Editing Immune Response Could Make Gene Therapy More Effective - UPJ Athletics

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Regenerative Medicine market.

Trusted Business Insights presents an updated and Latest Study on Regenerative Medicine Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Regenerative Medicine market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

The global regenerative medicine market size was USD 23,841.5 Million in 2018 and is Projected to Reach USD 151,949.5 Million by 2026, Exhibiting a CAGR of 26.1% between 2019 and 2026.

We have updated Regenerative Medicine Market with respect to COVID-19 Impact.Inquire before buying

Regenerative medicine (RM) involves using cells, tissues, or genetic material to treat and manage diseases. Regenerative medicine is an emerging field that aims to repair, replace or regenerate damaged tissue or organ. The U.S. National Institutes of Health includes cell therapy, gene therapy, biomaterials and tissue engineering into regenerative medicine. Regenerative medicine holds potential to treat incurable chronic diseases and conditions such as Alzheimer disease, Parkinsons disease, diabetes and others. According to the Alliance for Regenerative Medicine, approximately around 1,028 clinical trials are ongoing on regenerative medicine worldwide. Around USD 13.3 Bn global financing were raised in 2018 by investment into regenerative medicine. The increased investment by key market players in the research and development of the regenerative medicine is one of the major factor anticipated to drive the regenerative medicine market growth during the forecast period.

Market Segmentation

Increased investment in the research and development of regenerative by the key market players is one of the major factor driving the global market

Increasing investment by private and government organization in the development of the regenerative medicine is one of the factors expected to propel regenerative medicine industry dynamics. For instance, in March 2018, SanBio Group signed an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LLC for the development and contract manufacturing of regenerative medicines. Rising prevalence of chronic and genetic disorders and increased healthcare expenditure by developed and developing countries are some of the key factors impelling the regenerative medicine market growth.

Additionally, presence of the strong product pipeline in stem cell and gene therapy by various research institutes and key market players is one if the major factor anticipated to boost the growth of the market during the forecast period of 2018-2026. However, the growing demand for organ transplantation in developed and developing countries and the commercialization of regenerative medicine are some of the key elements anticipated to supplement the growth of the regenerative medicine market trends throughout the forecast period. Increased use of skin substitutes, grafts, bone matrix and other tissue engineered regenerative medicine is one of the prominent factor for the growth of the market.

Based on the type, the regenerative medicine industry segments includes cell therapy, gene therapy, tissue engineering, and platelet rich plasma. On the basis of the application, the market is segmented into orthopedics, wound care, oncology, and others.

On the basis of distribution channel, the global regnerative medicine segments includes hospitals, clinics, and others. Cell therapy segmented is expected to register comparatively high CAGR during the forecast period due to increased research and product development in the field of stem cells.Regional Analysis

Asia Pacific is anticipated to register comparatively higher CAGR during the forecast period due to increased adoption of the platelet rich plasma therapy and growing awareness among the population about stem cell therapy and regenerative medicine

North America generated maximum revenue of USD 9,128.2 Mn in 2018 and is expected to dominate the market throughout the forecast period. Due to presence of substantial number of key market players based in U.S., presence of research institutes involved in development of novel therapeutics and availability of advanced technologies are attributive to the high number of clinical trials in North America. Asia Pacific is anticipated to witness exponential growth during the forecast period owing to expansion of infrastructure and facilities to accelerate stem cell research in developing countries. In April 2013, the Japan Ministry of Health, Labor and Welfare approved Regenerative Medicine law.

Asia Pacific Regenerative Medicine Market Size, 2018

The imposition of the law increased the number of the clinical development of regenerative and cell-based therapies. This led to drive the growth of the regenerative medicine market in the region. Additionally, Chinese government has approved several research related to human embryonic stem cells in order to encourage researchers to explore the clinical potential of these cells in China. Furthermore, rising aging population, increasing medical needs, and changing lifestyle are some of the other factors influencing the growth of the global regenerative market in the Asia Pacific region. Latin America, and Middle East & Africa region hold large potential for the market during 2019-2026.

Key Market Drivers

CELGENE CORPORATION, Medtronic, and American CryoStem Corporation Account for the Highest Market Share in Terms of Revenue

CELGENE CORPORATION, is a leading player in the global regenerative medicines, owing to its strong portfolio in wound care and orthopedics and more investment in the research and development of the regenerative medicine. In order to strengthen the market position, key market players are focusing on the introduction of organ development and treatment of chronic diseases in the global market. CELGENE CORPORATION, Medtronic, and American CryoStem Corporation, dominated the regenerative medicine market in 2018. Other players operating in the market are Avita Medical, Osiris Therapeutics, Inc., Tissue Regenix, Wright Medical Group N.V., Smith & Nephew, Integra LifeSciences Corporation and others.

List of Companies Profiled

Report Coverage

The potential to directly alter human genes was first recognized nearly more than 50 years ago. Cell and gene therapy, represent overlapping fields of biomedical research with similar therapeutic goals. Regenerative medicine also comprises of therapeutic tissue engineering and biomaterials engineered substances used in medical applications to supplement or replace a natural body function. The increased number of the clinical trials and the use of the regenerative medicine for the development of the medicine to treat chronic diseases are some of the factors propelling the regenerative medicine market trends.

The report provides qualitative and quantitative insights on the regenerative medicine industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market is segments include type, application, distribution channel, and geography. On the basis of the type, the market is segmented into cell therapy, gene therapy, tissue engineering and platelet rich plasma. On the basis of the application, the market is segmented into orthopedics, wound care, oncology and others. On the basis of distribution channel, the regenerative medicine market is segmented into hospitals, clinics and others. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.

Along with this, the regenerative medicine market report comprises analysis of the industrydynamics and competitive landscape. Various key insights provided in the report are prevalence and incidence of diabetes by key countries, advancements in insulin delivery devices, recent industry developments such as mergers & acquisitions, pricing analysis, technological advancements, and key industry trends.

SEGMENTATION

By Product

By Application

By Distribution Channel

By Geography

Key Industry Developments

In 2018, Novartis received EU approval for one-time gene therapy Luxturna, which has been developed to restore vision in people with rare and genetically-associated retinal disease.

In 2018, Novartis received EU approval for its CAR-T cell therapy, Kymriah.In 2017, Integra LifeSciences launched its product, Integra Dermal Regeneration Template Single Layer Thin for dermal repair defects reconstruction in a one-step procedure.

Looking for more? Check out our repository for all available reports on Regenerative Medicine in related sectors.

Quick Read Table of Contents of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read the original:
Global regenerative medicine market size was USD 23841.5 Million in 2018 and is Projected to Reach USD 151949.5 Million by 2026, Exhibiting a CAGR of...

In an August 28 special issue of the peer-reviewed online journal OBM Transplantation, stem cell biotechnology company Asymmetrex has now published a report describing how its technology for determining the specific dosage of therapeutic tissue stem cells works. The new technology is poised to revolutionize stem cell science and stem cell medicine by giving the long-needed means to quantity their essential focus, tissue stem cells.

BOSTON, Sept. 1, 2020 /PRNewswire-PRWeb/ --Stem cell biotechnology company, Asymmetrex, has been counting tissue stem cells like those used for bone marrow and cord blood transplantation therapies for a few years now. Recently, the company announced the issue of patents for its first-in-kind technology both in the U.S. and the U.K. However, until last Friday, August 28, Asymmetrex had not reported in the peer-reviewed academic literature how it achieves this feat that had been pursued by many distinguished labs for more than six decades.

Now in a report published in a special issue of OBM Transplantation, a peer-review journal for transplantation medicine research, Asymmetrex completes its introduction of the new technology to the fields of stem cell science and stem cell medicine. The report is the second invited article published in a special issue focused on the "Isolation and Characterization of Adult Therapeutic Cells."

The new report describes Asymmetrex's discovery of mathematical formulas, call algorithms, that can be used to determine the number of stem cells in complex tissue cell preparations, like experimental samples or patient treatments. The stem cell counting algorithms are specific for different types of tissue stem cells. So, the algorithms defined for blood stem cells are distinct from the algorithms for liver stem cells, or lung stem cells. Once an algorithm is defined by the Asymmetrex technology, it can be used repeatedly as a simple, rapid, and inexpensive test to determine the quantity and dosage of its specific tissue stem cell type.

Asymmetrex's founder and director, James L. Sherley, M.D., Ph.D., anticipated the August publication of the new algorithms in a talk given earlier at the 6th Annual Perinatal Stem Cell Society Congress in March of this year. Then and now, he says that he believes, "Now that the tissue stem cell counting algorithms are available, everything will change" in stem cell science and medicine.

Prior to Asymmetrex's technology, there was no method for counting tissue stem cells in research, medicine, or for any other of their many uses. So, the impact of the stem cell counting algorithms in research and medicine is far-reaching. Such information is a game changer for accelerating progress in stem cell science and stem cell medicine, including improving treatments like gene therapy whose success depends on targeting tissue stem cells. There will also be tremendous gains in cell biomanufacturing, drug development, and environmental toxicology, all whose capabilities are currently limited by the lack of a facile means to quantify tissue stem cells.

To make the new counting technology readily accessible for evaluation by the greater academic, medical, and industrial stem cell communities, Asymmetrex provides free tissue stem cell counting on its company website.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company's U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the "AlphaSTEM Test") for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

SOURCE Asymmetrex, LLC

Original post:
New Report Begins a New Era of Stem Cell Science and Medicine: Stem Cell Biotechnology Company Asymmetrex Tells How It Counts Therapeutic Tissue Stem...

As we get older, many of our bodys processes start slowing down. For instance, a cut on the hand will take longer to heal after middle age than in youth. That said, it still heals.

Unfortunately, this isnt the case for the cells at the back of the eye, which simply dont repair much after we pass age 65. This can lead to age-related macular degeneration (AMD), the primary cause of vision loss in older adults. Over 2 million cases were reported in the U.S. in 2010, and the National Eye Institute estimates AMD will affect more than 3.5 million adults in the country by 2030.

Researchers at UC Santa Barbara have overcome a major hurdle in creating a platform to test therapies for this disease, the most common form of which currently has no treatment. The results appear in the journal PLOS ONE.

Our sharpest vision occurs at the center of the retina, in an area called the macula. This region is packed full of cones, the cells that are necessary for seeing in detail, said author Pete Coffey, a researcher at UCSBs Neuroscience Research Institute. They are the cells that are involved in reading, recognizing faces, the ability to drive, et cetera.

Just behind them is a layer of retinal pigment epithelial (RPE) cells. These are responsible for maintaining the health of our rods and cones, the eyes photo receptors. And these are the cells that stop working properly in AMD.

Age-related macular degeneration comes in two forms. Wet AMD occurs when blood vessels infiltrate the retina. There are treatments for this variety, which aim to prevent the growth of blood vessels where theyre not wanted.

However, roughly nine out of ten cases are what scientists call dry AMD, which involves progressive degeneration of the macula simply due to the inability of the RPE cells to heal. And while ophthalmologists can identify the disorders onset early on, there are currently no treatments for dry AMD.

Part of the struggle of finding a treatment option is that weve not been able to really model the progression of the disease in cell culture or in animals, said lead author Lindsay Bailey-Steinitz, a doctoral student in the Department of Molecular, Cellular, and Developmental Biology.

Bailey-Steinitz and her collaborators set out with two objectives in mind. The first was to understand what might be going on at the cellular level as the disease progresses. The other was to develop a model that could be used to test therapeutics.

As the RPE cells flounder in their efforts to repair themselves, a hole develops in this layer of the retina that continues to expand. Bailey-Steinitz aimed to recreate this hole in the lab. She cultured RPE cells on a plate with an electrode, then she zapped them. This created a hole very similar to the one that appears in AMD.

However, these were young cells, so they began healing and mending this hole. Thats great for the cells, but not for the team, which was trying to model the disease. So Bailey-Steinitz shocked the cells again. She found that after 10 pulses of electricity over the course of 10 days, the cells were no longer able to effectively repair the damage.

An overview of Coffey and Bailey-Steinitzs experiment.

Photo Credit: LINDSAY BAILEY-STEINITZ

To shed light on how the RPE cells responded to this stress, Bailey-Steinitz sequenced their RNA to figure out what proteins they were synthesizing in their damaged state. She found that some of the most important genes involved in the RPE cells function were suppressed, especially if the cells had been shocked multiple times.

The team also saw changes in gene expression that matched conditions seen in AMD. Whats more, the matrix which provides structural and biochemical support to the RPE cells also changed in ways that resembled the disease pathology.

I wasnt surprised that the RPE profile was down-regulated, Coffey said. If someone gives you a kick, then youre not going to feel well.

But, for that immunology to change and the matrix around the cells as well and to look similar to exactly that profile you see in AMD, I was very surprised.

Now that theyve recreated a similar profile in cultured cells as in the actual disease, the team is progressing to bigger holes, around six millimeters in diameter. Bailey-Steinitz is also planning a similar experiment with older cells, which show a decreased ability to heal.

If we can improve this setup, then weve got a therapeutic testbed for AMD, Coffey said.

Funding for this research came from the William K. Bowes Jr. Foundation, Garland Initiative for Vision, and the California Institute for Regenerative Medicine.

Read the original post:
Seeing Progress - The UCSB Current